Organovo Holdings, Inc. (NYSE MKT: ONVO) is an early
commercial stage company focusing on the development and commercialization of
functional human tissues for use in drug discovery and medical research.
Utilizing its proprietary three-dimensional bioprinting technology, the company
enables reproducible, automated creation of living human tissues that mimic the
form and function of native tissues in the body. Organovo’s exVive3D™ product
portfolio includes a recently launched 3D human liver tissue for use in
toxicology and preclinical drug testing. The company plans to expand upon its
existing product portfolio in the latter half of 2016 through the launch of its
exVive3D human kidney tissue.
Since launching its 3D human liver tissue on April 1, 2014,
the company has made significant strides toward increasing its market share
within the $50 billion research and development sector of the pharmaceutical
industry. Earlier this month, Organovo reported that it had already recording
total contract bookings for its innovative product amounting to approximately
$1.94 million, including $0.29 million in existing revenue. Among these orders,
the company secured partnerships with top 25 global pharmaceutical companies,
as well as additional public pharmaceutical companies of all sizes in the
United States, Europe and Asia.
“Response to the exVive3D human liver tissue has been
strong, and in line with our expectations,” Keith Murphy, chief executive
officer of Organovo, stated in a news release. “We continue to expect this
tissue to grow into the tens of millions in annual revenue, and that it has
$100M+ revenue potential.”
For Organovo, fiscal year 2015 was filled with milestones
that should provide the company with a strong platform to realize sustainable
returns moving forward. The release of the exVive3D human liver tissue set the
stage for a host of industry recognition – including being named among the ‘Top
10 Innovations of 2014’ by The Scientist magazine and ‘The World’s Top 10 Most
Innovative Companies of 2015’ by Fast Company magazine. Additionally, Organovo
diversified its market potential through a partnership with L’Oreal USA to
develop 3D printed skin tissues for product evaluation, marking the company’s
first foray into the beauty industry.
The company’s current momentum following the successful
release of its initial product could be a promising indication of Organovo’s
future growth potential. For prospective shareholders, the recent
commercialization of its exVive3D human liver tissue, as well as the continued
development of its human kidney tissue product, makes Organovo an exciting
investment opportunity to put on radar.
For more information, visit www.organovo.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
